Nuclear medicine firm MDS of Ottawa recorded a loss from continuing operations in the second quarter of fiscal year 2010 (end-April 30).
MDS reported revenues from continuing operations of $56 million (U.S.) in its second quarter of fiscal year 2010, compared with $65 million in the second quarter of fiscal 2009. Loss from continuing operations was $52 million in the second quarter, compared with a loss of $6 million in the second quarter of fiscal 2009. The increase in loss is due to a $14 million after-tax corporate restructuring charge and a $27 million noncash foreign exchange revaluation loss.
Including discontinued operations, MDS reported a net loss of $90 million in the second quarter of fiscal 2010, compared with a net loss of $17 million in the same quarter last year. MDS sold its Analytical Technologies and Pharma Services businesses in September 2009.
Related Reading
MDS changes name to Nordion, March 16, 2010
MDS inks deals to sell Pharma Services units, February 12, 2010
MDS names Anderson as chairman, February 2, 2010
MDS to lay off 150 in Toronto, February 1, 2010
MDS blames isotope shortage for poor Q4, January 22, 2010
Copyright © 2010 AuntMinnie.com
